Clinetica Biosciences International, Inc. today announced the appointment of Mr. Giles Osborne, CA, to Clinetica's Scientific Advisory Board. In this capacity Giles will assist with Clinetica's global information systems, investor relations and strategic planning initiatives in addition to compilation of Clinetica's annual financial statements and corporate tax returns.
With a background in general practice, including audit, accounting, and taxation work, Giles' experience has included involvement in the audit of organizations across a range of industries, as well as a broad base of experience in personal and corporate tax work. He has a particular interest in working with technology-oriented companies in their early years. Giles also has eight years of operational experience in the software industry, where he worked at the director level for Systems Union (now Infor), a mid-market financial accounting system author and vendor. Currently, Giles serves as Manager at Parker Prins Seel Chartered Accountants www.parkerprinseel.com. In welcoming Giles to the Scientific Advisory Board, Mr. Mohamed Jagani (CEO & President of Clinetica) was quoted as saying, "we are honored to welcome Mr. Osborne to Clinetica's Scientific Advisory Board. Mr. Osborne will work with current CFO (Mr. Elton Lau) to help build a robust in-house Finance & Accounting function within Clinetica."
Giles received his Chartered Accountancy Designation in 1994. After articling with BDO Dunwoody in Ottawa, Giles moved to Deloitte & Touche for four years before joining Systems Union. Giles is a native of Nova Scotia and enjoys sailing and karate in his spare time.
This news release contains forward-looking statements that are subject to risks and uncertainties relating to Clinetica's future financial and business performance, as well as any other predictive statements that depend on future events or conditions, or that include words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "may," "will," "estimate" or similar expressions of futurity. You should not place undue reliance on any forward-looking statements, which represent the company's statements only as of the date of this news release and are not intended to give any assurance as to actual future events. Factors that might cause future events to differ include: operational and personnel challenges that could result from management changes; the ability to execute our strategy during management transitions; the ongoing need for early and late phase drug development services; project cancellations and timing issues; our ability to attract and retain qualified personnel; our ability to continue providing our services effectively, including the quality or accuracy of the data or reports provided and our ability to meet agreed-upon schedules; the ability and willingness of our clients to continue to spend on research and development at rates comparable to or greater than historical levels; trends or events affecting the CRO industry and the demand for CRO services; government regulation, including regulatory standards applicable to CRO services; evolving industry standards and technological changes; and general business and economic conditions. Events relating to Clinetica Biosciences, Inc. could differ materially from those anticipated in these forward-looking statements. Although these statements are based upon assumptions company management believes to be reasonable based upon available information, they are subject to the foregoing risks and uncertainties. Please note that Clinetica Biosciences, Inc. assumes no obligation to update any of the forward-looking statements in this release, except as required by applicable local laws and/or regulations. For more information, please contact our investor relations department at ir@clinetica.com.
About Clinetica Biosciences International, Inc.
Clinetica Biosciences International, Inc. is a management
consulting and contract drug development corporation providing strategic consulting,
drug development and support services to clients in the biopharmaceutical
industry. Clinetica applies innovative technologies, therapeutic expertise
and a commitment to quality to help its clients and partners maximize returns
on their R&D investments and accelerate the delivery of safe and effective
therapeutics to patients.
To learn more about Clinetica Biosciences International, Inc. please visit
http://www.clinetica.com or call our
Corporate Headquarters at +1 (877) BIO-PHRM or +1 (877) 246 – 7476.